Fortress Biotech Framtida tillväxt
Future kriterier kontrolleras 2/6
Fortress Biotech s intäkter förväntas minska med 73.3% per år medan dess årliga intäkter förväntas växa med 42.1% per år. EPS förväntas falla med 87.5% per år.
Viktig information
-73.3%
Tillväxttakt i vinsten
-87.49%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 24.7% |
| Intäkternas tillväxttakt | 42.1% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Low |
| Senast uppdaterad | 18 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • Jun 05
FBIO: Cash Reserves And Journey Stake Will Drive Future Upside Potential
Analysts have raised their price target on Fortress Biotech stock to $5.00 from $4.50, citing a higher estimated value for the company’s cash position and its Journey Medical stake following the recent Q1 update. What's in the News Analysts raised the Fortress Biotech price target to $5.00 from $4.50, citing an updated assessment of the company’s cash position and its stake in Journey Medical after the recent Q1 update.Seeking Alpha • May 29
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
Summary Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO’s recent windfall from the Menkes disease drug sale positions it to easily pay $16 million in deferred FBIOP preferred dividends. FBIOP dividends, deferred for nearly two years, could total $4.69 per share if paid by June 15, 2026, benefiting significant insider holders. FBIO appears undervalued, with cash exceeding the sum of equity market cap, debt, preferred stock at par, and deferred dividends by $24 million. Read the full article on Seeking AlphaUppdatering av berättelse • May 12
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.Uppdatering av berättelse • Apr 25
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.Uppdatering av berättelse • Apr 11
FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.Uppdatering av berättelse • Mar 27
FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Uppdatering av berättelse • Mar 12
FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).Uppdatering av berättelse • Feb 26
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Uppdatering av berättelse • Feb 11
FBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Analysartikel • Feb 05
Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...Uppdatering av berättelse • Jan 28
FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.Uppdatering av berättelse • Jan 12
FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).Uppdatering av berättelse • Dec 26
FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earningsAnalysartikel • Dec 16
Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...Uppdatering av berättelse • Dec 12
FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.Analysartikel • Oct 05
Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
Uppdatering av berättelse • Aug 19
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.Analysartikel • Aug 17
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...Ny berättelse • Jul 06
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Analysartikel • Mar 11
Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Analysartikel • Oct 29
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...Analysartikel • Jul 26
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...Analysartikel • Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...Analysartikel • Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 134 | 21 | N/A | N/A | 2 |
| 12/31/2026 | 80 | 91 | N/A | N/A | 1 |
| 3/31/2026 | 66 | 119 | 158 | 158 | N/A |
| 12/31/2025 | 63 | -2 | -66 | -66 | N/A |
| 9/30/2025 | 62 | -5 | -81 | -66 | N/A |
| 6/30/2025 | 59 | -24 | -95 | -80 | N/A |
| 3/31/2025 | 58 | -51 | -89 | -74 | N/A |
| 12/31/2024 | 58 | -56 | -95 | -80 | N/A |
| 9/30/2024 | 82 | -58 | -102 | -102 | N/A |
| 6/30/2024 | 83 | -49 | -100 | -99 | N/A |
| 3/31/2024 | 85 | -63 | -113 | -110 | N/A |
| 12/31/2023 | 85 | -69 | -136 | -128 | N/A |
| 9/30/2023 | 62 | -86 | -150 | -141 | N/A |
| 6/30/2023 | 63 | -104 | -176 | -168 | N/A |
| 3/31/2023 | 64 | -100 | -182 | -176 | N/A |
| 12/31/2022 | 76 | -95 | -202 | -179 | N/A |
| 9/30/2022 | 78 | -97 | -196 | -170 | N/A |
| 6/30/2022 | 82 | -93 | -181 | -149 | N/A |
| 3/31/2022 | 81 | -74 | -179 | -142 | N/A |
| 12/31/2021 | 69 | -65 | -133 | -117 | N/A |
| 9/30/2021 | 64 | -38 | -113 | -98 | N/A |
| 6/30/2021 | 53 | -33 | -110 | -101 | N/A |
| 3/31/2021 | 44 | -43 | -89 | -83 | N/A |
| 12/31/2020 | 46 | -47 | -91 | -84 | N/A |
| 9/30/2020 | 43 | -57 | -99 | -88 | N/A |
| 6/30/2020 | 43 | -54 | -92 | -81 | N/A |
| 3/31/2020 | 43 | -54 | -102 | -92 | N/A |
| 12/31/2019 | 37 | -40 | N/A | -95 | N/A |
| 9/30/2019 | 34 | -45 | N/A | -92 | N/A |
| 6/30/2019 | 30 | -51 | N/A | -101 | N/A |
| 3/31/2019 | 27 | -53 | N/A | -96 | N/A |
| 12/31/2018 | 27 | -73 | N/A | -99 | N/A |
| 9/30/2018 | -107 | -61 | N/A | -98 | N/A |
| 6/30/2018 | -65 | -69 | N/A | -98 | N/A |
| 3/31/2018 | -22 | -72 | N/A | -98 | N/A |
| 12/31/2017 | 17 | -65 | N/A | -81 | N/A |
| 9/30/2017 | 155 | -74 | N/A | -78 | N/A |
| 6/30/2017 | 109 | -60 | N/A | -62 | N/A |
| 3/31/2017 | 61 | -55 | N/A | -46 | N/A |
| 12/31/2016 | 16 | -55 | N/A | -46 | N/A |
| 9/30/2016 | 4 | -50 | N/A | -35 | N/A |
| 6/30/2016 | 3 | -55 | N/A | -31 | N/A |
| 3/31/2016 | 1 | -49 | N/A | -30 | N/A |
| 12/31/2015 | 1 | -48 | N/A | -20 | N/A |
| 9/30/2015 | 1 | -40 | N/A | -17 | N/A |
| 6/30/2015 | 1 | -27 | N/A | -14 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: FBIO s intäkter förväntas minska under de kommande 3 åren ( -73.3% per år).
Resultat vs marknad: FBIO s intäkter förväntas minska under de kommande 3 åren ( -73.3% per år).
Höga tillväxtresultat: FBIO s intäkter förväntas minska under de kommande 3 åren.
Intäkt vs marknad: FBIO s intäkter ( 42.1% per år) förväntas växa snabbare än US marknaden ( 11.9% per år).
Hög tillväxtintäkter: FBIO s intäkter ( 42.1% per år) förutspås växa snabbare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om FBIO s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/09 15:00 |
| Aktiekurs vid dagens slut | 2026/06/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Fortress Biotech, Inc. bevakas av 13 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |